Rose Hill Life Sciences is investigating psilocybin in combination with structured rehabilitation for patients with chronic stroke. The approach pairs a carefully supported psychedelic session with defined motor practice to support engagement in rehabilitation and to track gains using validated motor scales.
Rose Hill Life Sciences and Johns Hopkins University Partnership on Motor Recovery
Partnership Overview
Rose Hill Life Sciences holds an exclusive license to technology from Johns Hopkins related to improving motor function after neurological injury using psychedelic therapy paired with recovery interventions. The partnership focuses on rigorous study design, patient safety, and measurable outcomes in people living with chronic stroke.
Restoration of Motor Function After Neurological Injury
Licensed Technology
The licensed invention describes methods that pair a carefully supported psilocybin session with defined motor practice. The aim is to support engagement in rehabilitation and to measure gains on validated motor scales.
Research Status and Objectives
The licensed interventions are being investigated for safety and efficacy within regulated research settings. Objectives include assessment of motor outcomes, patient experience, durability of effect, and tolerability. Rose Hill Life Sciences remains committed to advancing responsible research that may improve the lives of stroke survivors worldwide.